Skip to content

The Epidemiology of Recurrent Spontaneous Abortion Associated With Thrombophilla

Shanghai First Maternity and Infant Hospital

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02990390
Enrollment
45000
Registered
2016-12-13
Start date
2016-11-30
Completion date
2019-10-31
Last updated
2016-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Pregnancy Loss

Brief summary

RSA is a multifactorial disorder resulting from genetic factors, anatomic factors, autoimmune disorders, endocrine dysfunction, thrombophilia, life style factors, and maternal infections. However, the underlying causes remain undetermined in up to 50% of cases. In this clinical cohort study, we intended to get an epidemiological evidence for patients with recurrent spontaneous abortion associated with thrombophilla.

Interventions

None listed

Sponsors

Shanghai First Maternity and Infant Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Woman who had 2 miscarriages before 12(th) week of gestation.Signed consent form.

Exclusion criteria

1. having experienced severe allergies, trauma history and/or operation history within 3 months; 2. with a history of mental illness and/or family history of mental illness 3. limb disabled 4. taking medicine within one month 5. suffering major events or having mood swings 6. with a history of recurrent pregnancy loss 7. having internal and surgical disease(after having variety of physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine routine) 8. chromosome aberrations in anyone of the couple.

Design outcomes

Primary

MeasureTime frame
D-Dimerthrough study completion, an average of 3 year

Secondary

MeasureTime frame
BMI in kg/m^2through study completion, an average of 3 year
platelet aggregation timethrough study completion, an average of 3 year
anticardiolipin antibodythrough study completion, an average of 3 year

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026